Open Access

Lactobacillli expressing llama VHH fragments neutralise Lactococcusphages

  • Anna Hultberg1, 7,
  • Denise M Tremblay2,
  • Hans de Haard3, 6,
  • Theo Verrips3, 4,
  • Sylvain Moineau2, 5,
  • Lennart Hammarström1 and
  • Harold Marcotte1Email author
BMC Biotechnology20077:58

DOI: 10.1186/1472-6750-7-58

Received: 10 May 2007

Accepted: 17 September 2007

Published: 17 September 2007



Bacteriophages infecting lactic acid bacteria (LAB) are widely acknowledged as the main cause of milk fermentation failures. In this study, we describe the surface-expression as well as the secretion of two functional llama heavy-chain antibody fragments, one binding to the major capsid protein (MCP) and the other to the receptor-binding proteins (RBP) of the lactococcal bacteriophage p2, by lactobacilli in order to neutralise lactococcal phages.


The antibody fragment VHH5 that is directed against the RBP, was fused to a c-myc tag and expressed in a secreted form by a Lactobacillus strain. The fragment VHH2 that is binding to the MCP, was fused to an E-tag and anchored on the surface of the lactobacilli. Surface expression of VHH2 was confirmed by flow cytometry using an anti-E-tag antibody. Efficient binding of both the VHH2 and the secreted VHH5 fragment to the phage antigens was shown in ELISA. Scanning electron microscopy showed that lactobacilli expressing VHH2 anchored at their surface were able to bind lactococcal phages. A neutralisation assay also confirmed that the secreted VHH5 and the anchored VHH2 fragments prevented the adsorption of lactococcal phages to their host cells.


Lactobacilli were able to express functional VHH fragments in both a secreted and a cell surface form and reduced phage infection of lactococcal cells. Lactobacilli expressing llama heavy-chain antibody fragments represent a novel way to limit phage infection.


Llamas, a member of the Camelidae family, produce heavy chain antibodies, a type of antibodies that lack the CH1 domain and light chains [1]. The antigen binding portion of these antibodies, called VHH, can be expressed at high levels in Saccharomyces cerevisiae [2]. VHH antibody fragments have already shown a considerable potential in several biotechnological applications such as decreasing the amount of smooth surface caries in a rat model [3], shortening disease duration, severity and viral load in a mouse model of rotavirus-induced diarrhea [4], and preventing phage infection of Lactococcus cells during milk fermentation [5, 6].

Virulent bacteriophages infecting lactic acid bacteria (LAB) are widely acknowledged as the main cause of milk fermentation failures and they are also responsible for the downgrade of fermented dairy products such as cheeses [7, 8]. Their ubiquity in dairy environments, biodiversity, and genomic plasticity are largely responsible for the difficulty in controlling phage infection [9, 10]. Consequently, several tactics have been proposed to curtail their proliferation in industrial settings [10]. The generation of phage neutralising VHH antibodies is one of the latest antiviral strategies that have been proposed to inhibit lactococcal phages [5, 6]. As a proof of concept, a panel of non-neutralising and neutralising VHH antibody fragments targeting the lactococcal isometric-headed 936-type phage p2, was recently obtained [5]. The direct addition of one of them (VHH5) to milk prevented the infection of the strain Lactococus lactis subsp. cremoris C2 by the virulent phage p2 during the manufacture of a Gouda-type cheese [6]. The VHH5 fragment effectively inhibited lactococcal phage infection by directly binding to the receptor-binding protein (RBP/ORF18) located at the distal part of the phage tail [5]. Recently, it was shown that other phages belonging to the predominant lactococcal 936 species, could also be neutralised by this antibody [11]. Moreover, some of the non-neutralising fragments, such as VHH2, were shown to bind to the major structural capsid protein (ORF11) of phage p2 [5].

Lactobacilli are also Gram-positive lactic acid bacteria that normally colonize the oro-gastrointestinal tract [12, 13]. Some Lactobacillus strains are believed to have health promoting properties and are used as supplements in dairy products, either alone or in combination with other microorganisms [14, 15]. Similarly to Lactococcus lactis strains, other carefully selected Lactobacillus strains are an integral part of industrial starter cultures that are added to milk for the manufacture of an array of fermented dairy products. Thus, their large-scale used in the food industry is well established and their long history of safe use has led to their status as a Generally Regarded As Safe (GRAS) microorganism. This GRAS status has led to reports in which lactobacilli were suggested as carriers for passive immunization through surface expression or secretion of various antibodies [16]. Recently, functional antibody fragments targeting pathogenic bacteria (Streptococcus mutans and Porphyromonas gingivalis) and a human virus (rotavirus) have been produced in lactobacilli [4, 1618] and shown to have an antimicrobial potential.

In this study, we have explored the possibility of producing functional VHH antibody fragments by lactobacilli in order to neutralise lactococcal phages. The in situ VHH production, in a secreted form or anchored to the cell surface, could potentially alleviate the need to add the VHH fragments directly to the fermentation medium, thereby reducing the costs of the technology.

Results and discussion

Construction of Lactobacillus paracasei strains expressing VHH fragments that bind to structural proteins of Lactococcus lactisphage p2

We expressed the VHH5 single-chain as a secreted product and the VHH2 as a surface anchored fusion protein in L. paracasei. This strategy was selected because it was previously shown that the addition of VHH5 to a culture medium prevented phage infection while VHH2 had no effect [5]. However, we reasoned that anchoring VHH2 to a cell surface might prevent phage infection by tittering out viral particles present in a medium. First, the VHH2-E-tag and VHH5-c-myc fragments were inserted into the Lactobacillus expression vector pLP401, respectively generating the vectors pLP402-VHH5-secreted and pLP401-VHH2-anchored (Fig. 1A and 1B).
Figure 1

Map of the Lactobacillus expression vectors. (A) pLP402-VHH5-secreted with a stop codon (TAA) inserted after the E-tag sequence, mediating secretion of the antibody fragment and (B) pLP401-VHH2-anchored mediating surface-anchored expression of antibody fragments by fusion to the last 244 amino acids of the Lactobacillus casei proteinase P. Pamy, Promotor sequence of the α-amylase gene of L. amylovorus; SS amy, signal sequence of the α-amylase gene of Lactobacillus amylovorus (36 amino acids); N-terminus amy, N-terminus (26 amino acids) of the α-amylase of L. amylovorus; deleted Tldh, remaining sequence after deletion of transcription terminator of the lactate dehydrogenase gene of L. casei; VHH5, VHH fragment against the receptor-binding protein of lactococcal phage p2; VHH2, VHH fragment against the major structural capsid protein of phage p2; Anchor, anchor sequence from the proteinase P gene of L. casei (244 amino acids); Tcbh, transcription terminator sequence of the conjugated bile acid hydrolase gene of Lactobacillus plantarum 80; Ampr, ampicillin-resistance gene; Ery, erythromycin-resistance gene.

The presence of pLP402-VHH5-secreted in L. paracasei was found to mediate the secretion of VHH5 into the medium (Fig 1A). The introduction of pLP401-VHH2-anchored into L. paracasei led to the cell surface expression of VHH2 by fusion to the C-terminal cell wall anchored domain of proteinase P (Fig. 1B). In these vectors, the VHH expression is under the control of the promoter of the amy gene (Fig. 1). This regulatable promoter is repressed by sugars transported by the phosphoenolpyruvate-dependent phosphotransferase systems (PTS). De-repression of the promoter and protein expression is obtained by growing the cells in the presence of non-PTS sugars such as mannitol. Both VHH fragments were tagged for detection with anti-E-tag or anti-myc-tag antibodies. The theoretical molecular mass of the anchored VHH2 and secreted VHH5 is 43 kDa and 23 kDa respectively after cleavage of the signal peptide (4 kDa) but containing the N-terminus (26 amino acids, 3.9 kDa) of the amylase protein fused to the VHH (Fig. 1).

Expression of the VHH fragments

VHH expression was analysed by immunoblotting of L. paracasei-transformed strains using monoclonal anti-E-tag antibodies or anti-myc antibodies. The culture supernatant and cell pellet of L. paracasei transformed with the pLP402-VHH5-secreted vector contained a protein of 23 kDa corresponding to the secreted mature VHH (Fig. 2A). An additional band of approx. 19 kDa in the supernatant of L. paracasei transformed with the pLP402-VHH5-secreted could also be observed, probably resulting from degradation. In all likelihood, the degradation did not occur in the binding part of the VHH but rather in the N-terminal part of the amylase protein fused to the VHH after cleavage of the signal peptide (Fig. 1).
Figure 2

Determination of the expression of VHH fragments by L. paracasei using Western blot assay. (A) lane 1, supernatant of pLP402; lane 2, supernatant of pLP402-VHH5-secreted showing the secreted mature VHH of 23 kDa and a degradation product of 19 kDa; lane 3, cell extracts of pLP402-VHH5-secreted showing the precursor VHH (signal peptide-VHH) of 26 kDa and the mature VHH of 23 kDa. (B) lane 1, cell extracts of pLP401-VHH2-anchored showing a anchored VHH2 of 46 kDa; lane 2, control VHH2-E-tag (supernatant from pLP402-VHH2-secreted); lane 3; cell extracts of pLP402.

The cell extract of L. paracasei transformed with pLP401-VHH2-anchored yielded a protein of approximatively 46 kDa (Fig. 2B). Surface expression of VHH2 on recombinant lactobacilli transformed with pLP401-VHH2-anchored was analysed by flow cytometry using an anti-E-tag antibody. The transformed pLP401-VHH2-anchored L. paracasei strain showed a strong positive signal when stained with the anti-E-tag antibody, whereas the same parental strain transformed with the vector pLP402 did not show any signal (Fig. 3). L. paracasei transformed with pLP402-VHH5-secreted did not show any surface expression in flow cytometry (data not shown). Taken altogether, these findings confirm the surface location of the VHH2-E-tag-anchored fusion construct on the cell.
Figure 3

Flow cytometry showing VHH2 expression on the surface of L. paracasei. L. paracasei transformed with the pLP401-VHH2-anchored (black filled). The negative control, L. paracasei containing the vector pLP402, did not show any signal (grey line).

Using purified VHH5 and VHH2 fragments as positive controls, we also estimated that the L. paracasei strain containing the vector pLP401-VHH2-anchored expressed about 103–104 molecules per cell (calculated from the VHH standard) while the L. paracasei strain carrying pLP402-VHH5-secreted, grown to an OD600 of 0.8, expressed about 500 ng of VHH fragments per ml of supernatant, corresponding to a production rate of roughly 5 × 104 VHH fragments/bacterium/hour.

Binding of the expressed VHH fragments to phage p2

Binding of the VHH fragments to their respective antigen was analysed by ELISA using homogenates of the L. paracasei pLP401-VHH2-anchored and supernatant from L. paracasei pLP402-VHH5-secreted. Both VHH fragments were able to bind to their antigen indicating that they are functional (Table 1). No activity was observed using extracts and supernatants from cultures of L. paracasei containing only the pLP402 vector. The Lactobacillus strain expressing the anchored VHH2 was also mixed with Lactococcus phage p2 and analyzed by scanning electron microscopy (SEM). Phage particles were found at the surface of the recombinant lactobacilli expressing the anchored VHH2 but not at the surface of L. paracasei containing only the pLP402 vector (Fig. 4).
Table 1

Binding of the expressed VHH fragments to phage p2 antigens by ELISA



Cell extractb


























a Supernatant from a culture grown until an OD600 nm of 0.8.

b Cell extract was made by sonication of 2.5 × 109 CFU in 1 ml of PBS.

c Undiluted or dilutions of supernatant and cell extract were added to the wells.

Figure 4

Scanning electron microscope (SEM) image. (A) Phage p2 particles binding to the recombinant L. paracasei expressing VHH2 anchored on the cell surface (approximately 20 times more binding than the control). (B) Control, L. paracasei containing only the vector pLP402 mixed with lactococcal phage p2. Arrows indicate the phage p2 particles. Bar = 1 μm.

Neutralisation of phage p2 by VHH2 and VHH5 expressed in lactobacilli

Finally, the ability of recombinant Lactobacillus strains to neutralise p2 phages was also studied. A fixed titer of phage (1,000 pfu) was mixed with supernatant or Lactobacillus cells expressing VHH. The supernatant from Lactobacillus pLP402-VHH5-secreted was shown to neutralise phage p2 by binding to its RBP and significantly inhibiting (86%) its adsorption to the host strain Lactococcus lactis MG1363. In comparison, almost no p2 phage particles were bound to the parental L. paracasei strain with or without the cloning vector pLP402 (Table 2). Interestingly, the surface expressed VHH2 was also able to inhibit phage infection of L. lactis cells, albeit to a lesser extent (31%) (Table 2). Thus, even though VHH2 (which is recognizing the major capsid protein) is non-neutralising when added as a monovalent fragment to a culture medium [5, 19], it can neutralise bacterial viruses when anchored at the surface of a lactic acid bacterium. As compared to other anti-phage strategies currently available, the above reported inhibitory effect of VHH (as a secreted or anchored product) would probably not be considered as a strong anti-phage system (7). However, lactic acid bacteria producing VHH could be used concomitantly with other strategies to increase the overall protection of starter cultures against phages, thereby providing a novel hurdle to control them.
Table 2

Percentage of phage p2 inhibition by bacterially produced VHH


% inactivationa




L. paracasei parental

1.8 ± 5.9

2.1 ± 1.0

L. paracasei + pLP402

4.6 ± 4.0

-4.4 ± 6.4

L. paracasei + pLP402-VHH5-secreted

86.0 ± 5.1


L. paracasei + pLP402-VHH2-anchored

3.4 ± 6.6

31.4 ± 2.8

a Mean ± standard deviation of at least three experiments

b 10 μl supernatant (approximately 5 ng VHH)

c 4 × 106 bacteria


It was previously shown that VHH5 fragments bind to some but not all 936-like phages [11], which is the most prevalent lactococcal phage group in the dairy industry [5, 9]. Moreover, it was recently shown that phage mutants no longer neutralised by VHH5 could be readily isolated in the laboratory [11]. Further strategies are thus needed to improve the broadness of the VHH protection and to prevent the emergence of new virulent phages. One possible approach could be the identification of more potent neutralising VHH fragments. Alternatively, the expression of multiple VHH fragments could enhance the protection and the applicability of the system. It should be noted that the VHH fragment should preferably be constitutively produced using an expression system devoid of antibiotic selection marker. Nonetheless, the proof of concept reported here univocally showed that the expression of anti-phage VHH by a LAB represents a novel tool to prevent phage infection. This method would be much more cost effective as the VHH fragments would be produced in situ in the fermentation medium, eliminating the need for additional purification of the VHH fragments.


Bacterial strains, phage, culturing conditions, and VHH expression

Escherichia coli DH5α was used as the cloning host strain and cells were grown in Luria-Bertani (LB) medium (10 g tryptone/litre, 5 g NaCl/litre, 5 g yeast extract/litre). E. coli transformants were selected on LB plates containing 100 μg/ml ampicillin. Lactobacillus paracasei (previously known as L. casei or L. zeae ATCC 393 pLZ15-) [20], transformed with the plasmids pLP402 [16], pLP402-VHH5-secreted or pLP401-VHH2-anchored, were selected on MRS (Difco) plates with 3 μg/ml erythromycin after cultivation anaerobically at 37°C for 48 h. The pLP402-VHH5-secreted and pLP401-VHH2-anchored vectors, respectively mediated the secretion of VHH5 fragments and the surface expression of VHH2 fragments under the transcriptional control of the regulatable α-amylase promoter. The α-amylase promoter is regulated by a negative feedback. It is repressed by PTS sugars such as glucose and lactose in L. paracasei. Growth in presence of non-PTS sugars, such as mannitol, derepresses the promoter and activate gene expression. Pre-cultures of L. paracasei were made by growing the cultures in LCM medium [21] supplemented with 1% glucose and 3 μg/ml of erythromycin when needed and incubating them at 37°C overnight. These cultures were used to inoculate (2%) LCM-Man medium supplemented with 0.5% mannitol and 3 μg/ml of erythromycin, which were then incubated at 37°C. Cells were harvested in the exponential growth phase at an optical density at 600 nm (OD600) of 0.8 (108 cfu/ml) [16, 21]. Lactococcus lactis MG1363 was grown at 30°C in M17 broth [22] supplemented with 0.5% glucose (GM17) (Difco). Lysate of the lactococcal phage p2 was prepared as described previously [23].

Construction of the Lactobacillus paracasei expression vectors pLP401-VHH2-anchor and pLP402-VHH5-secreted

The VHH2 encoding gene was cut out from the phagemid vector pUR3824 [5] at the restriction sites SfiI and NotI and ligated into pCANTAB 5E (Amersham Pharmacia Biotech) in order to fuse it with the E-tag. PCR amplification of the VHH2-E-tag was performed to add restriction sites for ClaI and XhoI to the VHH2-E-tag using primers ClaI-VHH: 5'-GCCATTGGAACTTACTCTGAAAA-3' and XhoI-VHH: 5'-CCGCTCGAGTGCGGCACGCGGTTCC-3'. Similarly, the VHH5-c-myc fragment was amplified by PCR from the pUR3825 [5] vector using the primers ClaI-VHH and c-myc-stop (5'-CCGCTCGAGTTATGCGGCACGCGGTTCC-3') and adding in the process the restriction sites ClaI and XhoI with a stop codon (TAA) after the c-myc gene. The VHH2-E-tag and VHH5-c-myc fragments were, after restriction cutting and purification, ligated into the Lactobacillus expression vector pLP401 (previously named pLP402) [16, 21] at the ClaI and XhoI sites to generate the vectors pLP401-VHH2-anchored and pLP402-VHH5-secreted. Transformation of L. paracasei was performed as previously described [16, 21]. Selection of positive clones was performed using MRS plates containing 3 μg/ml erythromycin. Lactobacilli containing pLP402-VHH2-secreted was also constructed, similarly to the pLP401-VHH2-anchored construct but with a stop (TAA) before the E- tag and was used as control in the Western blot assays.

Preparation of samples for the enzyme-linked immunosorbent assay and Western blot analysis

After growth in presence of 0.5% mannitol, cells were washed, treated with lysosyme and disrupted by sonication as previously described [17]. For ELISA, cell debris were removed by centrifugation for 10 min at 10,000 × g and the supernatant containing the protein extracts were stored at -20°C before use. For the Western blot analyses, Laemmli loading buffer was added to the sonicated cell extracts and the samples were boiled for 5 min, centrifuged (15 min, 10,000 × g) after which the supernatants were stored at -20°C. Supernatants from cultures of L. paracasei secreting VHH5 were filtered (0.45 μm) and concentrated 50 times using an ultrafiltration unit (Amicon). Protein concentrations were determined by the BioRad protein assay (BioRad Laboratories). For Western blot, the concentrated supernatant was boiled for 5 min in Laemmli buffer.

Flow cytometry

After growth in presence of mannitol, 100 μl of each lactobacilli culture (107 bacteria) containing the vectors pLP402 or pLP401-VHH2-anchored were washed three times in PBS by centrifugation (10,000 × g for 15 min) before resuspension in 100 μl of PBS. An equal amount of mouse anti-E-tag antibody (Amersham Bioscience) diluted 1/200 was added and the samples were incubated on ice for 1 h. The washing procedure in PBS was repeated and the samples were resuspended in 100 μl of PBS and mixed with 100 μl cy2-labeled donkey anti-mouse antibodies (Jackson Immunoresearch Laboratories) (final dilution 1/200) and incubated on ice for 30 min. After washing, the samples were resuspended in one ml of PBS and analysed in a FACSCalibur machine (Becton Dickinson).

Western blotting

Samples were run on a 12% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane (Hybond-ECL, Amersham-Biosciences). The membranes were blocked with 5% (w/v) milk powder diluted in PBS-Tween 20 (0.05% v/v) (PBS-TM) and incubated for 1 h at room temperature with monoclonal mouse anti-myc 9E10 (Abcam Inc.) for VHH5-secreted or anti-E-tag antibodies for VHH2-anchored, both diluted 1/1,000 in PBS-TM, followed by HRP (horse radish peroxidase) labelled goat anti-mouse antibodies (1/1,000) (DAKO) for 1 h. The washed membrane was then developed with ECL Plus Western Blotting Kit (Amersham-Bioscience) according to the manufacturer's instructions.

Enzyme-linked immunosorbent Assay

First, 96-well (Maxisorp) plates were coated with 10 μg/ml of recombinant major structural capsid protein (MCP, the VHH2 antigen) or recombinant receptor-binding protein (RBP, the VHH5 antigen) [5] and left overnight at 4°C. After washing with PBS containing 0.05% Tween 20 (PBS-T), dilutions of the concentrated supernatants from L. paracasei cultures secreting VHH5 as well as of the extract from cells anchoring VHH2, were added and incubated at room temperature for 1 h. Concentrated supernatants and cell extracts from cultures of L. paracasei containing only the vector pLP402 were used as negative controls. Purified VHH2 and VHH5 from E. coli, respectively with an E-tag and a c-myc tag [5], were used in standard curves to evaluate the amount of VHH produced by various L. paracasei transformants.

Plates were washed twice and a mouse anti-E-tag antibody (1/1,000) was added to the wells previously incubated with the extracts from L. paracasei VHH2-anchored. A mouse anti-myc antibody 9E10 (1/1,000) (Abcam Inc.) was added to the wells previously incubated with the purified VHH2 and VHH5 as well as supernatant containing VHH5 secreted by L. paracasei cells. After 1 h incubation at room temperature, plates were washed twice and an alkaline phosphatase conjugated rabbit anti-mouse antibody (1/1,000) (DAKO) was added to the plates. Following incubation for 1 h at room temperature, diethanolamine buffer (1 M, pH 10.0) containing 1 mg/ml of pNPP substrate (Sigma-Aldrich) was added to the wells. The absorbance was read at 405 nm in a Vmax Kinetic Microplate reader (Molecular Devices).

Scanning electron microscopy (SEM)

A culture of L. paracasei anchoring VHH2 was washed in PBS and 100 μl (106 bacteria/ml) was mixed with 500 μl (5 × 1010 pfu/ml) of the lactococcal phage p2 and left at room temperature for 1 h. The mixture was fixed in 2% glutaraldehyde diluted in 0.1 M sodium cacodylate and 0.1 M sucrose, and finally added onto a 0.1 mg/ml poly-L-lysine coated RC58 filter. After dehydration (70% ethanol 10 min, 95% ethanol 10 min, 99% ethanol 10 min), the samples were sputtered and analysed by SEM (JEOL JSM-820) at 15 kV.

Phage inhibition assay

The protocol for this assay was adapted from the lactococcal 936-phage adsorption experiments of Geller et al. [24]. L. paracasei strains were grown to an optical density of 0.8 at 600 nm (OD600) in LCM-Man medium containing the appropriate antibiotic. Cells were harvested and the supernatant was filtered (0.45 μm) for immediate use. Cell pellets were suspended in 0.25 volume of LCM. Approximately 1,000 plaque-forming unit (pfu) of lactococcal phage p2 (30 μl) were mixed on ice with 10 μl of L. paracasei supernatant (about 5 ng VHH5), cells (4 × 106 bacteria) or LCM. After incubation of 4 h on ice, the mixture was centrifuged 5 min at 16,100 × g at 4°C. Phage titer was determined as followed in triplicate using 10 μl of the supernatant. Ten μl were added to 3 ml of GM17 supplemented with 0.75% agar and containing 100 μl of an overnight culture of the host strain Lactococcus lactis MG1363. The mixture was then poured onto a GM17 plate (1% agar), incubated overnight at 30°C, and the number of plaques were counted. The percentage of inhibition was calculated by dividing the titer of the phage with L. paracasei bacteria or supernatant by the phage titer in LCM. The quotient was subtracted from 1 and multiplied by 100. The experiment was repeated at least three times and the means were calculated for the pool of experiments. Because the amy promoter is repressed by lactose, co-culture of both strains in milk to test inhibition of phage infection was not tested with the present system.



We thank Pim Hermans (Unilever research and Development, Vlaardingen, The Netherlands) for help with culturing the phages and Neha Pant (Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet, Sweden) for help with flow cytometry. We are grateful to Claudia Bergeron for her technical work on the phage neutralization assays. This study was supported by the Swedish Research Council (VR). S. M. would like to acknowledge the Natural Sciences and Engineering Research Council (NSERC) of Canada for funding part of this study.

Authors’ Affiliations

Division of Clinical Immunology at the Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital in Huddinge
Groupe de recherche en écologie buccale, Faculté de médecine dentaire, Félix d'Hérelle Reference Center for Bacterial Viruses, Université Laval
Unilever Research and Development
Cellular Architecture and Dynamics (CAD), Utrecht University
Département de biochimie et de microbiologie, Faculté des sciences et de génie, Université Laval
Cellular Architecture and Dynamics (CAD), Utrecht University


  1. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R: Naturally-occurring antibodies devoid of light-chains. Nature. 1993, 363: 446-448. 10.1038/363446a0.View ArticleGoogle Scholar
  2. Frenken LGJ, van der Linden RHJ, Hermans PWJJ, Bos JW, Ruuls RC, de Geus B, Verrips CT: Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol. 2000, 78: 11-21. 10.1016/S0168-1656(99)00228-X.View ArticleGoogle Scholar
  3. Krüger C, Hultberg A, Marcotte H, Hermans P, Bezemer S, Frenken LG, Hammarström L: Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries. Appl Microbiol Biotechnol. 2006, 72: 732-737. 10.1007/s00253-006-0347-0.View ArticleGoogle Scholar
  4. Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarström Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, Borén T, Marcotte H, Hammarström L: Lactobacilli expressing VHH antibody fragments from llama confer protection against rotavirus-induced diarrhea. J Infect Dis. 2006, 194: 1580-1588. 10.1086/508747.View ArticleGoogle Scholar
  5. de Haard HJW, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LGJ, Verrips CT: Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. J Bacteriol. 2005, 187: 4531-4541. 10.1128/JB.187.13.4531-4541.2005.View ArticleGoogle Scholar
  6. Ledeboer AM, Bezemer S, de Haard HJW, Schaffers IM, Verrips CT, Vliet C, van Düsterhöft EM, Zoon P, Moineau S, Frenken LGJ: Preventing phage lysis of Lactococcus lactis in cheese production using a neutralising heavy-chain antibody fragment from llama. J Dairy Sci. 2002, 85: 1376-1382.View ArticleGoogle Scholar
  7. Moineau S: Applications of phage resistance in lactic acid bacteria. Antonie van Leeuwenhoek. 1999, 76: 377-382. 10.1023/A:1002045701064.View ArticleGoogle Scholar
  8. Moineau S, Tremblay D, Labrie S: Phages of lactic acid bacteria: from genomics to industrial applications. ASM News. 2002, 68: 388-393.Google Scholar
  9. Deveau H, Labrie SJ, Chopin MC, Moineau S: Biodiversity and classification of lactococcal phages. Appl Environ Microbiol. 2006, 72: 4338-4346. 10.1128/AEM.02517-05.View ArticleGoogle Scholar
  10. Sturino JM, Klaenhammer TR: Engineered bacteriophage-defence systems in bioprocessing. Nat Rev Microbiol. 2006, 4: 395-404. 10.1038/nrmicro1393.View ArticleGoogle Scholar
  11. Tremblay D, Tegoni M, Spinelli S, Campanacci V, Blangy S, Huyghe C, Desmyter A, Labrie S, Moineau S, Cambillau C: Receptor-binding protein of Lactococcus lactis phages: Identification and characterization of the saccharide receptor-binding site. J Bacteriol. 2006, 188: 2400-2410. 10.1128/JB.188.7.2400-2410.2006.View ArticleGoogle Scholar
  12. Ahrne S, Nobaek S, Jeppsson B, Adlerberth L, Wold AE, Molin G: The normal Lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol. 1998, 85: 88-94. 10.1046/j.1365-2672.1998.00480.x.View ArticleGoogle Scholar
  13. Lidbeck A, Nord CE: Lactobacilli and the normal human anaerobic microflora. Clin Infect Dis. 1993, S181-187. Suppl 4
  14. Macfarlane GT, Cummings JH: Probiotics, infection and immunity. Curr Opin Infect Dis. 2002, 15: 501-506.View ArticleGoogle Scholar
  15. Tannock GW: A special fondness for lactobacilli. Appl Environ Microbiol. 2004, 70: 3189-3194. 10.1128/AEM.70.6.3189-3194.2004.View ArticleGoogle Scholar
  16. Krüger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, van Dolleweerd C, Ma JK, Hammarström L: Single chain producing lactobacilli: a new tool for in situ delivery of passive immunity. Nat Biotech. 2002, 20: 702-706. 10.1038/nbt0702-702.View ArticleGoogle Scholar
  17. Krüger C, Hultberg A, Marcotte H, van Dollenweerd C, Hammarström L: Passive immunization by lactobacilli expressing single-chain antibodies against Streptococcus mutans. Mol Biotech. 2005, 31: 221-231. 10.1385/MB:31:3:221.View ArticleGoogle Scholar
  18. Marcotte H, Kõll-Klais P, Hultberg A, Zhao Y, Gmür R, Mändar R, Mikelsaar M, Hammarström L: Expression of single-chain antibody against RgpA protease of Porphyromonas gingivalis in Lactobacillus. J Appl Microbiol. 2006, 100: 256-263. 10.1111/j.1365-2672.2005.02786.x.View ArticleGoogle Scholar
  19. Spinelli S, Desmyter A, Verrips CT, de Haard HJW, Moineau S, Cambillau C: Lactococcal bacteriphage p2 receptor-binding protein structure suggests a common ancestor gene with bacterial and mammalian viruses. Nat Struct Mol Biol. 2006, 13: 85-89. 10.1038/nsmb1029.View ArticleGoogle Scholar
  20. Acedo-Félix E, Pérez-Martínez G: Significant differences between Lactobacillus casei subsp. casei ATCC 393T and commonly used plasmid-cured derivative revealed by a polyphasic study. Int J Syst Evol Microbiol. 2003, 53: 1-9. 10.1099/ijs.0.02651-0.View ArticleGoogle Scholar
  21. Pouwels PH, Leer RJ, Boersma WJ: The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. J Biotechnol. 1996, 44: 183-192. 10.1016/0168-1656(95)00140-9.View ArticleGoogle Scholar
  22. Terzaghi BE, Sandine WE: Improved medium for lactic streptococci and their bacteriophages. Appl Microbiol. 1975, 29: 807-813.Google Scholar
  23. Jarvis AW: Serological studies of a host range mutant of a lactic streptococcal bacteriophage. Appl Environ Microbiol. 1978, 36: 785-789.Google Scholar
  24. Geller BL, Ngo HT, Mooney DT, Su P, Dunn N: Lactococcal 936-species phage attachment to surface of Lactococcus lactis. J Dairy Sci. 2005, 88: 900-907.View ArticleGoogle Scholar


© Hultberg et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.